ClinicalTrials.gg
CompletedNCT06643377Updated Oct 20, 2026Results posted

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

A Phase 1 interventional study of Enlicitide in Healthy and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Updated Oct 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
16th of 32
27 · median 26
Started
2024
with 1 other
Phase 1
25 of 32
2 open now
Registered
28th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 25 in phase 1, and was the 28th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (meaning the kidneys do not work properly) and to people who are in good health. The researchers believe that the total amount of enlicitide in a person's body measured during the 24 hours after a dose will be similar in people with severe renal impairment and in healthy people.

03

Conditions studied

  • Healthy
  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • (BMI) between 18 and 40 kg/m\^2, inclusive
  • On a stable dose of statin therapy; no changes to dose or type of statin therapy for at least 2 months

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History or presence of renal artery stenosis
  • Had a functioning renal transplant in the past 5 years and is taking transplant medication
  • History of gastrointestinal (GI) disease which might affect food and drug absorption

Panel A: Participants with Severe Renal Impairment:

- History of any illness, other than hypercholesterolemia and Renal Impairment

Panel B: Healthy Participants:

- History of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases, other than hypercholesterolemia

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Panel A: Severe Renal Impairment

    Participants with severe renal impairment receive enlicitide once daily (QD) for 28 days.

    Drug: Enlicitide

  • Experimental
    Panel B: Healthy

    Healthy participants receive enlicitide QD for 28 days.

    Drug: Enlicitide

Interventions

  • Oral tablet

    Also known as: Enlicitide decanoate, MK-0616

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide

    The AUC0-24 of enlicitide in plasma is reported.

    Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose

  2. Maximum Plasma Concentration (Cmax) of Enlicitide

    The Cmax of enlicitide is reported.

    Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose

  3. Time to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma

    The Tmax of plasma enlicitide is reported.

    Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose

  4. Apparent Plasma Clearance at Steady State (CLss/F) of Enlicitide

    CLss/F of enlicitide is reported.

    Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose

  5. Apparent Plasma Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide

    The plasma Vz/F of enlicitide was to be reported. Vz/F was not reported, because blood for PK was only collected for 24 hours post dose at steady state (Day 28), thus the terminal phase could not be characterized, and Vz/F could not be calculated.

    Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose

  6. Number of Participants Who Experience One or More Adverse Events (AEs)

    The number of participants with ≥1 AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 42 days

  7. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 28 days

07

Results

Posted Oct 20, 2026

Participant flow

Adult male and female participants on background statin therapy who were either healthy, or had severe renal impairment, were recruited.

Participant flow — Overall Study
MilestonePanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Started1512
Completed1512
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide

The AUC0-24 of enlicitide in plasma is reported.

Time frame:
Day 28 predose and 1, 3, 8, and 24 hours postdose
Reported as:
Geometric mean · hr*nmol/L
Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide
hr*nmol/LPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide347 (296 to 407)236 (206 to 271)
Statistical analysis
  • Panel A: Severe Renal Impairment Participants vs Panel B: Healthy Participants · Gmr: 1.47 · 90% CI 1.25 to 1.73
PrimaryMaximum Plasma Concentration (Cmax) of Enlicitide

The Cmax of enlicitide is reported.

Time frame:
Day 28 predose and 1, 3, 8, and 24 hours postdose
Reported as:
Geometric mean · nmol/L
Maximum Plasma Concentration (Cmax) of Enlicitide
nmol/LPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Maximum Plasma Concentration (Cmax) of Enlicitide17.1 (14.3 to 20.3)13.2 (11.1 to 15.7)
Statistical analysis
  • Panel A: Severe Renal Impairment Participants vs Panel B: Healthy Participants · Gmr: 1.29 · 90% CI 1.07 to 1.56
PrimaryTime to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma

The Tmax of plasma enlicitide is reported.

Time frame:
Day 28 predose and 1, 3, 8, and 24 hours postdose
Reported as:
Median · Hour
Time to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma
HourPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Time to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma5.48 (1.00 to 24.03)1.00 (0.83 to 23.45)
PrimaryApparent Plasma Clearance at Steady State (CLss/F) of Enlicitide

CLss/F of enlicitide is reported.

Time frame:
Day 28 predose and 1, 3, 8, and 24 hours postdose
Reported as:
Geometric mean · Liters/hour
Apparent Plasma Clearance at Steady State (CLss/F) of Enlicitide
Liters/hourPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Apparent Plasma Clearance at Steady State (CLss/F) of Enlicitide37.1 ± 25.354.5 ± 20.5
PrimaryApparent Plasma Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide

The plasma Vz/F of enlicitide was to be reported. Vz/F was not reported, because blood for PK was only collected for 24 hours post dose at steady state (Day 28), thus the terminal phase could not be characterized, and Vz/F could not be calculated.

Time frame:
Day 28 predose and 1, 3, 8, and 24 hours postdose

No measurements were reported for this outcome.

PrimaryNumber of Participants Who Experience One or More Adverse Events (AEs)

The number of participants with ≥1 AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 42 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
ParticipantsPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Number of Participants Who Experience One or More Adverse Events (AEs)52
PrimaryNumber of Participants Who Discontinue Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 28 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Intervention Due to an AE
ParticipantsPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Number of Participants Who Discontinue Study Intervention Due to an AE30

Adverse events

Collected over Up to ~42 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: Severe Renal Impairment Participants0/15 (0%)3/15 (20%)4/15 (26.7%)
Panel B: Healthy Participants0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent serious events
Most frequent serious events
EventPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Acute myocardial infarctionCardiac disorders1/150/12
Diastolic dysfunctionCardiac disorders1/150/12
InfluenzaInfections and infestations1/150/12
PneumoniaInfections and infestations1/150/12
HyponatraemiaMetabolism and nutrition disorders1/150/12
Acute kidney injuryRenal and urinary disorders1/150/12
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/150/12
Hypertensive urgencyVascular disorders1/150/12
HypotensionVascular disorders1/150/12
Most frequent other events
Most frequent other events
EventPanel A: Severe Renal Impairment ParticipantsPanel B: Healthy Participants
Urinary tract infectionInfections and infestations0/151/12
MyalgiaMusculoskeletal and connective tissue disorders0/151/12
Abdominal painGastrointestinal disorders1/150/12
DiarrhoeaGastrointestinal disorders1/150/12
VomitingGastrointestinal disorders1/150/12
Metabolic acidosisMetabolism and nutrition disorders1/150/12
Muscle spasmsMusculoskeletal and connective tissue disorders1/150/12
AnxietyPsychiatric disorders1/150/12
CoughRespiratory, thoracic and mediastinal disorders1/150/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panel A: Severe Renal Impairment ParticipantsPanel B: Healthy ParticipantsTotal
Mean70.6 ± 10.967.0 ± 3.869.0 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: Severe Renal Impairment ParticipantsPanel B: Healthy ParticipantsTotal
Female7512
Male8715
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: Severe Renal Impairment ParticipantsPanel B: Healthy ParticipantsTotal
Hispanic or Latino41014
Not Hispanic or Latino11112
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: Severe Renal Impairment ParticipantsPanel B: Healthy ParticipantsTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American415
White111021
More than one race000
Unknown or Not Reported000
08

Study locations

5 sites
  • Velocity Clinical Research, New Smyrna Beach ( Site 0003)
    Edgewater, Florida 32132, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0006)
    Hallandale, Florida 33009, United States
  • Nature Coast Clinical Research - Inverness ( Site 0002)
    Inverness, Florida 34452, United States
  • Jacksonville Center for Clinical Research ( Site 0004)
    Jacksonville, Florida 32216, United States
  • Genesis Clinical Research, LLC ( Site 0001)
    Tampa, Florida 33603, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jun 2025, 7 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartActual
Nov 22, 2024
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Primary outcomes
7 edited
What changed in the outcomes
  • EditedArea Under the Plasma Concentration versusVersus Time Curve fromFrom Time 0 to 24 hoursHours (AUC0-24) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
  • EditedMaximum plasma concentrationPlasma Concentration (Cmax) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
  • EditedTime to maximum plasma concentrationMaximum Plasma Concentration (Tmax) of enlicitideEnlicitide in plasmaPlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
  • EditedApparent Plasma Clearance at Steady State (CLCLss/F) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
  • EditedApparent volumePlasma Volume of distribution during terminal phaseDistribution During Terminal Phase (Vz/F) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
  • EditedNumber of participants who experience oneParticipants Who Experience One or more adverse eventsMore Adverse Events (AEs)Time frame: Up to approximately 42 days
  • EditedNumber of participants who discontinue study intervention dueParticipants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 28 days
Oct 20, 2026
Documents
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Primary outcomes 7 edited
    What changed in the outcomes
    • EditedArea Under the Plasma Concentration versusVersus Time Curve fromFrom Time 0 to 24 hoursHours (AUC0-24) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
    • EditedMaximum plasma concentrationPlasma Concentration (Cmax) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
    • EditedTime to maximum plasma concentrationMaximum Plasma Concentration (Tmax) of enlicitideEnlicitide in plasmaPlasmaTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
    • EditedApparent Plasma Clearance at Steady State (CLCLss/F) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
    • EditedApparent volumePlasma Volume of distribution during terminal phaseDistribution During Terminal Phase (Vz/F) of enlicitide in plasmaEnlicitideTime frame: Pre-dose and at designated time points up to 24 hours post dose on Day 28 → Day 28 predose and 1, 3, 8, and 24 hours postdose
    • EditedNumber of participants who experience oneParticipants Who Experience One or more adverse eventsMore Adverse Events (AEs)Time frame: Up to approximately 42 days
    • EditedNumber of participants who discontinue study intervention dueParticipants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 28 days
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06643377
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Nov 22, 2024
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion